Pathological Assessment of Men with Grade Group 2 Prostate Cancer

Pathological Assessment of Men with Grade Group 2 Prostate Cancer

Purpose: A variety of treatment options are now available for men with localized prostate cancer (PC); however, there is still debate in determining how and when to intervene for Grade Group (GG) 2 disease. Our study aims to formulate strategies to identify men at risk of upgrading and having adve...

Full description

Saved in:

Bibliographic Details
Main Authors:	Anika Jain, Lawrence Kim, Manish I. Patel
Format:	Article
Language:	English
Published:	Korean Society for Sexual Medicine and Andrology 2025-07-01
Series:	The World Journal of Men's Health
Subjects:	active surveillance grade group 2 pathology prostate cancer prostatic neoplasms watchful waiting
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Temporal trend in risk of prostate cancer death in men with favourable-risk prostate cancer
by: Frederik F. Thomsen, et al.
Published: (2024-04-01)

Correlation of expression of Cyclin D1 and E-cadherin with gleason grade, serum prostate specific antigen levels and prostatic volume in prostatic carcinoma
by: C Aatirah, et al.
Published: (2023-07-01)

High level of interleukin-10 in serum after therapy is characteristic of prostate carcinoma patients with high Gleason score, high tumor volume and present peritumoral infiltration
by: Jovanović Dejan, et al.
Published: (2021-01-01)

A selective CutMix approach improves generalizability of deep learning-based grading and risk assessment of prostate cancer
by: Sushant Patkar, et al.
Published: (2024-12-01)

Rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer—A population‐based cohort study
by: Rano Matta, et al.
Published: (2020-10-01)

Patients with small prostates and low-grade intravesical prostatic protrusion – A urodynamic evaluation
by: Han Jie Lee, et al.
Published: (2017-10-01)

Management of Small Renal Masses: Literature and Guidelines Review
by: Antonio Silvestri, et al.
Published: (2025-08-01)

Prospective validation study of a combined urine and plasma test for predicting high-grade prostate cancer in biopsy naïve men
by: Torben Brøchner Pedersen, et al.
Published: (2025-01-01)

Comparative Study of Gleason 7 (3+4) and (4+3) Prostatic Adenocarcinomas with Prognostic Criteria and Immunohistochemical Profiles of AMACR, PSA and Ki-67
by: Clarice F. E. M. Osório, et al.
Published: (2025-01-01)

Intralesional and perilesional radiomics strategy based on different machine learning for the prediction of international society of urological pathology grade group in prostate cancer
by: Zhiping Li, et al.
Published: (2025-07-01)

A national survey of physicians regarding active surveillance for low-risk thyroid cancer in Korea
by: Min Joo Kim, et al.
Published: (2025-01-01)

Targeted Prostate Biopsies Overestimate International Society of Urological Pathology Grade Group, Particularly in Smaller Tumors
by: Lisa J. Kroon, et al.
Published: (2025-05-01)

Standardized Ultrasound Evaluation for Active Surveillance of Low-Risk Thyroid Microcarcinoma in Adults: 2024 Korean Society of Thyroid Radiology Consensus Statement
by: Ji Ye Lee, et al.
Published: (2024-11-01)

Diagnostic value of 18F-PSMA-1007 PET/CT for predicting the pathological grade of prostate cancer
by: Xiao-Bo Niu, et al.
Published: (2024-12-01)

Unveiling key pathomic features for automated diagnosis and Gleason grade estimation in prostate cancer
by: Valentina Brancato, et al.
Published: (2025-07-01)

Morphological markers of secretory activity in prostatic adenocarcinoma
by: Janković-Veličković Ljubinka, et al.
Published: (2007-01-01)

A Machine Learning Model for Prostate Cancer Prediction in Korean Men
by: Sukjung Choi, et al.
Published: (2024-11-01)

Detecting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions Using T2w-Derived Radiomics Feature Maps in 3T Prostate MRI
by: Laura J. Jensen, et al.
Published: (2024-11-01)

Advanced prostatic carcinomas with low serum levels of prostate-specific antigen
by: Cerović Snežana J., et al.
Published: (2002-01-01)

TWIK Complex Expression in Prostate Cancer: Insights into the Biological and Therapeutic Significances of Potassium Ion Channels in Clinical Cancer
by: Abdulaziz Alfahed
Published: (2025-05-01)

Characterisation of Multiparametric Magnetic Resonance Imaging of the Prostate in Younger Men with Normal Prostate-specific Antigen Within the PROBASE Study
by: Rouvier Al-Monajjed, et al.
Published: (2025-05-01)

The Clinical Applications of Tissue Biomarkers in Prostate Cancer
by: Peter Lonergan, Samuel Washington, Maxwell Meng, Renu Eapen
Published: (2020-10-01)

Impact of Prebiopsy Multiparametric Magnetic Resonance Imaging on Prostate Cancer Detection in Switzerland
by: Thomas Paul Scherer, et al.
Published: (2025-03-01)

Factor of combined pathology in geriatric patients with prostate adenoma
by: I. G. Leshchenko, et al.
Published: (2020-12-01)

Comparative Assessment of Serum Prostate Specific Antigen (PSA) and Inosine Monophosphate Dehydrogenase-2 (IMPDH-2) as Predictors of Aggressive Prostate Cancer
by: Ahmed Mohammed Umar, et al.
Published: (2025-05-01)

Association of Perineural Invasion of Adenocarcinoma in Prostate Biopsy with Pathological and Clinical Outcomes
by: Rita Rueangrong, et al.
Published: (2025-08-01)

Assessing the Cause of Death for Men with Prostate Cancer Using Official Mortality Statistics or a Dedicated Cause of Death Committee: Results from 30-year ERSPC Rotterdam Data
by: Sebastiaan Remmers, et al.
Published: (2025-01-01)

Immunohistochemical expression of androgen receptors in prostate carcinoma and benign prostatic hyperplasia
by: Trivunić-Dajko Sandra, et al.
Published: (2020-01-01)

Effect of Glison index on survival of patients with localized prostate cancer in Samara region
by: R. D. Andreeva, et al.
Published: (2022-05-01)

Estimated length of stay calculated by “diagnosisrelated groups” in patients with prostate cancer: a retrospective analysis
by: Daniel Melecchi Freitas, et al.
Published: (2021-10-01)

Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel
by: Tae Hwan Kim, et al.
Published: (2023-11-01)

Histopathological evaluation and grading for prostate cancer: current issues and crucial aspects
by: Vittorio Agosti, et al.
Published: (2024-10-01)

SIU-ICUD: Localized Prostate Cancer: Pathological Factors That Influence Outcomes and Management
by: Gladell P. Paner, et al.
Published: (2025-06-01)

Correlation of clinically significant prostate cancer sites across multiparametric MRI, prostate biopsy, and whole-mount pathology for optimal prostate biopsy strategy
by: Matteo Pacini, et al.
Published: (2025-02-01)

Optimal use of prostate specific antigen for prostate cancer screening
by: Miočinović Ranko, et al.
Published: (2013-01-01)

Significance of microvessel density in prostate cancer core biopsy
by: Salapura-Dugonjić Aleksandra, et al.
Published: (2015-01-01)

Optimising prostate cancer pathways: Improving post‐biopsy waiting times in a tertiary centre
by: Shayan Soroush, et al.
Published: (2025-07-01)

Metastatic prostate cancer presenting as a posterior mediastinal mass: A rare presentation
by: Muhammad Haider, et al.
Published: (2023-03-01)

Cost-effectiveness of watchful waiting versus immediate emergency department transfer after epinephrine autoinjector use in Canada
by: Yiwei Yin, et al.
Published: (2025-01-01)

A Systematic Review of the Association between Psychological Resilience and Improved Psychosocial Outcomes in Prostate Cancer Patients: Could Resilience Training Have a Potential Role?
by: David Robert Harry Christie, et al.
Published: (2025-01-01)